|
1
|
Ling V: Multidrug resistance: Molecular
mechanism and clinical relevance. Cancer Chemother Pharmacol.
40:(Suppl). S3–S8. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gottesman MM: Mechanisms of cancer drug
resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sauna ZE, Smith MM, Müller M, Kerr KM and
Ambudkar SV: The mechanism of action of multigrug-resistance-linked
P-glycoprotein. J Bioenerg Biomembr. 33:481–491. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gottesmann MM, Fojo T and Bates SE:
Multidrug resistance in cancer: Role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gillet JP and Gottesman MM: Mechanisms of
multidrug resistance in cancer. Methods Mol Biol. 596:47–76. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Higgins CF: Multiple molecular mechanism
for multidrug resistance transporters. Nature. 446:749–757. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ward AB, Szewczyk P, Grimard V, Lee CW,
Martinez L, Doshi R, Caya A, Villaluz M, Pardon E, Cregger C, et
al: Structures of P-glycoprotein reveal its conformational
flexibility and an epitope on the nucleotide-binding domain. Proc
Natl Acad Sci USA. 110:13386–13391. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lyman GH, Khorana AA, Kuderer NM, Lee AY,
Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates
LE, et al: American Society of Clinical Oncology Practice: Venous
thromboembolism prophilaxis and treatment in patients with cancer:
American Society of Clinical Oncology clinical practice guideline
update. J Clin Oncol. 31:2189–2204. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sørensen HT, Mellemkjaer L, Olsen JH and
Baron JA: Prognosis of cancers associated with venous
thromboembolism. N Engl J Med. 343:1846–1850. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Heit JA, Silverstein MD, Mohr DN,
Petterson TM, O'Fallon WM and Melton LJ III: Risk factors for deep
vein thrombosis and pulmonary embolism: A population based
case-control study. Arch Intern Med. 160:809–815. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Khorana AA, Francis CW, Culakova E,
Kuderer NM and Lyman GH: Frequency, risk factors, and trends for
venous thromboembolism among hospitalized cancer patients. Cancer.
110:2339–2346. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Beer JH, Haeberli A, Vogt A, Woodtli K,
Henkel E, Furrer T and Fey MF: Coagulation markers predict survival
in cancer patients. Thromb Haemost. 88:745–749. 2002.PubMed/NCBI
|
|
13
|
Callader NS, Varki N and Rao LV:
Immunohistochemical identification of tissue factor in solid
tumors. Cancer. 70:1194–1201. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kataoka H, Uchino H, Asada Y, Hatakeyama
K, Nabeshima K, Sumivoshi A and Koono M: Analysis of tissue factor
and tissue factor pathway inhibitor expression in humanoid
colorectal carcinoma cell lines and metastatic sublines to the
liver. Int J Cancer. 72:878–884. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Uno K, Homma S, Satoh T, Nakanishi K, Abe
D, Matsumoto K, Oki A, Tsunoda H, Yamaguchi I, Nagasawa T, et al:
Tissue factor expression as a possible determinant of
thromboembolism in ovarian cancer. Br J Cancer. 96:290–295. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Antoniou D, Pavlakou G, Stathopoulos GP,
Karvdis I, Chondrou E, Papageorgiou C, Dariotaki F, Chaimala D and
Veslemes M: Predictive value of D-dimer plasma levels in response
and progressive disease in patients with lung cancer. Lung Cancer.
53:205–210. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tomimaru Y, Yano M, Takachi K, Kishi K,
Miyashiro I, Ohue M, Ohigashi H, Sasaki Y, Ishikawa O and Imaoka S:
Correlation between pretreatment d-dimer levels and response to
neoadjuvant chemotherapy in patients with advanced esophageal
cancer. Dis Esophagus. 21:281–287. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lwaleed BA and Cooper AJ: Tissue factor
expression and multidrug resistance in cancer: Two aspects of a
common cellular response to a hostile milieu. Med Hypotheses.
55:470–473. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Piccin A, Murphy WG and Smith OP:
Circulating microparticles: Pathophysiology and clinical
implications. Blood Rev. 21:157–171. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hugel B, Martínez MC, Kunzelmann C and
Freyssinet JM: Membrane microparticles: Two sides of the coin.
Physiology (Bethesda). 20:22–27. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Haubold K, Rink M, Spath B, Friedrich M,
Chun FK, Marx G, Amirkhosravi A, Francis JL, Bokemeyer C, Eifrig B
and Langer F: Tissue factor procoagulant activity of plasma
microparticles is increased in patients with early-stage prostate
cancer. Thromb Haemost. 101:1147–1155. 2009.PubMed/NCBI
|
|
22
|
Hron G, Kollars M, Weber H, Sagaster V,
Quehenberger P, Eichinger S, Kyrle PA and Welterman A: Tissue
factor-positive microparticles: Cellular origin and association
with coagulation activation in patients with colorectal cancer.
Thromb Haemost. 97:119–123. 2007.PubMed/NCBI
|
|
23
|
Zwicker JI, Kos CA, Johnston KA, Liebman
HA, Furie BC and Furie B: OC-06 tissue factor-bearing
microparticles are associated with an increased risk of venous
thromboembolic events in cancer patients. Thromb Res. 120:(Suppl).
S1432007. View Article : Google Scholar
|
|
24
|
Zwicker JI, Liebman HA, Neuberg D, Lacroix
R, Bauer KA, Furie BC and Furie B: Tumor-derived tissue
factor-bearing microparticles are associated with venous
thromboembolic events in malignancy. Clin Cancer Res. 15:6830–6840.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Manly DA, Wang J, Glover SL, Kasthuri R,
Liebman HA, Key NS and Mackman N: Increased microparticle tissue
factor activity in cancer patients with venous thromboembolism.
Thromb Res. 125:511–512. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lechner D and Weltermann A: Circulating
tissue factor-exposing microparticules. Thromb Res. 122(Suppl 1):
S42–S54. 2008.PubMed/NCBI
|
|
27
|
Thaler J, Ay C, Mackman N, Bertina RM,
Kaider A, Marosi C, Key NS, Barcel DA, Scheithauer W, Kornek G, et
al: Microparticle-associated tissue factor activity, venous
thromboembolism and mortality in pancreatic, gastric, colorectal
and brain cancer patients. J Thromb Haemost. 10:1363–1370. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Thaler J, Ay C, Mackman N, Metz-Schimmerl
S, Stift J, Kaider A, Müllauer L, Gnant M, Scheithauer W and
Pabinger I: Microparticle-associated tissue factor activity in
patients with pancreatic cancer: Correlation with
clinicopathological features. Eur J Clin Invest. 43:277–285. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bharthuar A, Khorana AA, Hutson A, Wang
JG, Key NS, Mackman N and Iyer R: Circulating microparticle tissue
factor, thromboembolism and survival in pancreaticobiliary cancers.
Thromb Res. 132:180–184. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tesselaar ME, Romijn FP, Van Der Linden
IK, Prins FA, Bertina RM and Osanto S: Microparticle-associated
tissue factor activity: A link between cancer and thrombosis? J
Thromb Haemost. 5:520–527. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nitori N, Ino Y, Nakanishi Y, Yamada T,
Honda K, Yanagihara K, Kosuge T, Kanai Y, Kitajima M and Hirohashi
S: Prognostic significance of tissue factor in pancreatic ductal
adenocarcinoma. Clin Cancer Res. 11:2531–2539. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Angelini A, Di Pietro R, Centurione L,
Castellani ML, Conti P, Porreca E and Cuccurullo F: Inhibition of
P-glycoprotein-mediated transport by S-adenosylmethionine and
cynarin in multidrug-resistant human uterine sarcoma MES-SA/Dx5
cells. J Biol Regul Homeost Agents. 26:495–504. 2012.PubMed/NCBI
|
|
33
|
Angelini A, Centurione L, Sancilio S,
Castellani ML, Conti P, Di Ilio C, Porreca E, Cuccurullo F and Di
Pietro R: The effect of the plasticizer diethylhexyl phthalate on
transport activity and expression of P-glycoprotein in parental and
doxo-resistant human sarcoma cell lines. J Biol Regul Homeost
Agents. 25:203–211. 2011.PubMed/NCBI
|
